概述

  • 产品名称Anti-KRIT1抗体
    参阅全部 KRIT1 一抗
  • 描述
    小鼠单克隆抗体to KRIT1
  • 经测试应用适用于: ELISAmore details
  • 种属反应性
    与反应: Human
    预测可用于: Mouse, Rat, Cow
  • 免疫原

    Recombinant fragment: AAFFTGQIFT KASPSNHKVI PVYVGVNIKG LHLLNMETKA LLISLKYGCF MWQLGDTDTC FQIHSMENKM SFIVHTKQAG LVVKLLMKLN GQLMPTERNS , corresponding to amino acids 637-736 of Human KRIT1 with a 26kDa tag

  • 阳性对照
    • KRIT1 transfected 293T cell lysate

性能

应用

Our Abpromise guarantee covers the use of ab54889 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA Use at an assay dependent dilution. Detection limit is approximately 0.03ng/ml as a capture antibody when used against the immunogen.

靶标

  • 功能Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin D1 levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.
  • 组织特异性Low levels in brain. Very weak expression found in heart and muscle.
  • 疾病相关Defects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1) [MIM:116860]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
  • 序列相似性Contains 4 ANK repeats.
    Contains 1 FERM domain.
  • 细胞定位Membrane. Cell junction. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
  • Information by UniProt
  • 数据库链接
  • 别名
    • Ankyrin repeat containing protein Krit1 antibody
    • CAM antibody
    • CCM 1 antibody
    • CCM1 antibody
    • Cerebral cavernous malformations 1 antibody
    • Cerebral cavernous malformations 1 protein antibody
    • Krev interaction trapped 1 antibody
    • Krev interaction trapped protein 1 antibody
    • KRIT 1 antibody
    • KRIT1 ankyrin repeat containing antibody
    • KRIT1 antibody
    • KRIT1_HUMAN antibody
    see all

Anti-KRIT1 antibody 图像

  • Detection of immunogen (recombinant fragment) at the indicated concentrations using ab54889 at 0.03ng/ml.

Anti-KRIT1 antibody (ab54889)参考文献

ab54889 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab54889.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"